Lundbeck announced that it has made available Onfi (clobazam tablets) for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥2 years of age. Onfi was first approved in October 2011 by the FDA and is a schedule C-IV controlled substance.
Onfi is a 1,5 benzodiazepine oral antiepileptic drug that is believed to exert its therapeutic effects through potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABAA receptor. Onfi is available in 5mg, 10mg, and 20mg dosage strength tablets.
For more information, call (866) 337-6996 or visit www.onfi.com.